Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Multiple sclerosis
•
Neurology
•
Neuro-immunology
What are potential pitfalls in the use of OCT to support a diagnosis of multiple sclerosis?
Related Questions
At what degree of lymphopenia do you switch/discontinue dimethyl fumarate in patients with multiple sclerosis?
Are there any precautions that should be taken when transitioning a patient with multiple sclerosis from one disease modifying therapy to another?
How frequently do you recommend ordering labs to monitor for side effects of disease-modifying therapies for multiple sclerosis?
Do you treat tumefactive multiple sclerosis differently than other forms of MS both in the acute and maintenance phase?
How do you decide on initial and sequential anti-CD20 therapy for patients with multiple sclerosis given the availability of rituximab, ocrelizumab, ublituximab, and ofatumumab?
How would you treat chorea in a patient with Sjögren’s syndrome and positive beta 2 glycoprotein I antibodies?
Would you proceed with anti-CD20 treatment in an MS patient who is VZV IgG negative in spite of vaccination in the last year?
How would you approach the decision to escalate DMT in a patient with relapsing multiple sclerosis who has two to three new T2 lesion but no clinical symptoms?
Would you consider anti-CD20 agents for treatment of multiple sclerosis in patients with history of breast cancer?
What is the diagnostic approach and management for suspected Hashimoto Encephalitis?
